A luminescent heterometallic multifunctional theranostic Eu-Pt 2 complex, [{cis-PtCl 2 (DMSO)} 2 Eu(L)(H 2 O)] has been synthesized, possessing two therapeutic Pt-centers as covalent DNA binders and one emissive Eu 3+ -center which is sensitized by platinumbased metal-to-ligand charge-transfer excited states.
Multifunctional cancer theranostic agents having multiple therapeutic and diagnostic centers in a single platform gains popularity in recent years. [1] [2] [3] Recently, there are few reports on heterometallic hairpin-shaped lanthanide-Pt 2 complexes for DNA recognition and magnetic resonance imaging (MRI) based theranostic agents or selectively delivering gadolinium to tumor cell nuclei. 4 In this regard, theranostic Gd
3+
-based platinum complexes reported 4c in which Gd 3+ and conjugated cis- [Pt(NH 3 ) 2 Cl] + -moieties act as MRI contrast and therapeutic centers, respectively. These complexes showed therapeutic efficiency along with improved MR imaging capability. However, their DNA-binding ability is limited because of only two available DNA-cross linking sites. In addition, the clinical use of platinum drugs is severely affected by drug resistance mediated by inadequate levels of platinum reaching to critical target DNA. 5 Notwithstanding with this progress, it is highly desirable to increase the DNA binding sites that significantly enhances platinum content at target site along with tagging of bright luminescent center as diagnostic probe. To this end, we report the design of multimodal targeted theranostic Eu-Pt 2 conjugate possessing four DNA binding sites which can effectively target nuclear DNA along with highly luminescent Eu 3+ center to enable interference-free live-tracking of the drug through fluorescence microscopy. Luminescent lanthanide complexes were widely exploited in various bioassays since they offer Herein, we demonstrate a multifunctional Eu-Pt 2 complex, [{cis-PtCl 2 (DMSO)} 2 Eu(L)(H 2 O)] (1) (Scheme 1) which has cytotoxic cis-[PtCl 2 (DMSO)] moieties enabling the DNA binding whereas, EuL unit acts as luminescent reporter. Thus, a combination of a luminescent imaging probe and a conjugated therapeutic agent in a single hybrid 5d-4f complex can provide real-time feedback on drug delivery, distribution and target site localization in a non-invasive manner through fluorescence microscopy. Other key design feature of this complex is having four potential DNA cross-linking sites through labile Pt-Cl bonds, thus higher level of activated platinum reaching DNA, a possible way to lower the drug resistance. Eu-Pt 2 complex 1 was prepared in a sequential manner (Scheme S1, ESI †) starting with a multidentate DTPA-bisamide ligand, 
transitions of Eu 3+ (Fig. 1b) (Fig. 1d) . Since DNA is the most important target for therapeutic platinum drugs, we attempted detailed binding studies of 1 with DNA. The hairpin-shaped complex 1 gets activated by aquation through substitution of chlorides by water generating potent cation, [Eu(L)(H 2 O){cis-Pt(OH 2 ) n/2 (DMSO)} 2 ] n+ (n = 1-4), which can readily cross-link with nucleobases of ds-DNA (Scheme S2, ESI †). The binding interaction of Eu-Pt 2 complex with calf-thymus DNA (CT-DNA) were studied using UV-vis titration, competitive displacement of ethidium bromide by fluorescence (K app = 4.9 x 10 5 M -1 ) , circular dichroism (CD) and isothermal titration calorimetry (ITC) (Fig. S6-S8 , ESI †). ITC titration plot (Fig. 2b ) also suggests unwinding of DNA helix and major structural deformation of DNA induced by Pt-DNA cross-links. 14 This structural distortion of DNA could be beyond cellular DNA repair machinery and thereby inhibit transcription and replication, triggering cell-death pathways. 5 The decrease in DNA migration rate in presence of Eu-Pt 2 compared to EuL in gel electrophoretic mobility assay using SC pUC19 DNA also suggest unwinding of supercoiled DNA helix by 1 (Fig. 2 c) . 15 We have observed significant enhancement of Eu-based luminescence intensity originating from (Fig. 2d) . Serum albumin proteins constitutes a major component in blood plasma proteins and plays important roles in drug transport and metabolism. The interaction of the EuPt 2 (Fig. 2d) . It exerts anticancer activity via extensive DNA-adduct formation through conjugated cis-[PtCl 2 (DMSO)] moieties in a similar mechanism to cisplatin.
The cellular internalization of the Eu-Pt 2 complex was investigated to probe diagnostic aspect of [Eu(L)(H 2 O)] utilizing long luminescence lifetime and intrinsic luminescence from Eu 3+ by confocal fluorescence microscopy (panel A, Fig. 3 ).
Theranostic Eu-Pt 2 complex showed significant cellular uptake within 4 h of incubation with HeLa cells. Staining with nuclear staining dye Hoechst 33258 demonstrate both nucleus and cytosolic distribution of the complex (panel C, Fig. 3 ). The red spots observed in some nuclei originate from luminescence from the Eu 3+ reporter tag in Eu-Pt 2 theranostic conjugate ( Fig.   S11 , ESI †).
In conclusion, we have developed a luminescent multimodal heterometallic Eu-Pt 2 theranostic system using sensitization and energy transfer from a conjugated Pt 2+ based chromophore to Eu 3+ . The complex shows strong binding propensity to DNA via formation of Pt-DNA cross-links through four potential DNA binding sites. The complex exhibit cytotoxicity through DNA damage and nuclear localization observed due to Eu-based f-f transition by fluorescence imaging. Thus, such systems will have great potential towards designing theranostic agents and delivery vehicles for cancer chemotherapy. Further studies are on towards designing potent lanthanide based theranostic agents as efficient drug delivery platform and understanding mechanism of their action.
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